تقرير
[
| العنوان: | [ |
|---|---|
| المؤلفون: | Singh, Simron, Halperin, Daniel, Myrehaug, Sten, Herrmann, Ken, Pavel, Marianne, Kunz, Pamela L, Chasen, Beth, Tafuto, Salvatore, Lastoria, Secondo, Capdevila, Jaume, García-Burillo, Amparo, Oh, Do-Youn, Yoo, Changhoon, Halfdanarson, Thorvardur R, Falk, Stephen, Folitar, Ilya, Zhang, Yufen, Aimone, Paola, de Herder, Wouter W, Ferone, Diego |
| المصدر: | Lancet ; ISSN:1474-547X ; Volume:403 ; Issue:10446 |
| بيانات النشر: | Elsevier Science |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) treatment. |
| نوع الوثيقة: | report article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1016/S0140-6736Test(24)00701-3; https://pubmed.ncbi.nlm.nih.gov/38851203Test |
| DOI: | 10.1016/S0140-6736(24)00701-3 |
| الإتاحة: | https://doi.org/10.1016/S0140-6736Test(24)00701-3 https://pubmed.ncbi.nlm.nih.gov/38851203Test |
| حقوق: | Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| رقم الانضمام: | edsbas.FAF3CB2C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S0140-6736(24)00701-3 |
|---|